scholarly journals An Integrated Artificial Intelligence Model for Efficiency Assessment in Pharmaceutical Companies During the COVID-19 Pandemic

Author(s):  
Mirpouya Mirmozaffari ◽  
Reza Yazdani ◽  
Elham Shadkam ◽  
Seyed Mohammad Khalili ◽  
Meysam Mahjoob ◽  
...  
Author(s):  
Ivan Khoo Yi ◽  
Andrew Fang Hao Sen

The overall purpose of this chapter will be to broadly explore both the existing and possible implementations of artificial intelligence (AI) in healthcare. The scope of this chapter will be explored from the unique perspectives of various stakeholders in the healthcare industry, namely the healthcare providers, patients, pharmaceutical companies, healthcare financial institutions, and policymakers. The chapter will seek to identify the potential benefits and pitfalls that faced by these stakeholders in implementing the use of AI, from the molecular level to a macroeconomics level; as well as seeking to understand the legal, professional, and ethical boundaries of the medical domain that are challenged as AI increasingly becomes irreversibly intertwined with the practice of medicine.


2019 ◽  
Vol 2019 ◽  
pp. 1-15 ◽  
Author(s):  
Nagasundaram Nagarajan ◽  
Edward K. Y. Yapp ◽  
Nguyen Quoc Khanh Le ◽  
Balu Kamaraj ◽  
Abeer Mohammed Al-Subaie ◽  
...  

Artificial intelligence (AI) proves to have enormous potential in many areas of healthcare including research and chemical discoveries. Using large amounts of aggregated data, the AI can discover and learn further transforming these data into “usable” knowledge. Being well aware of this, the world’s leading pharmaceutical companies have already begun to use artificial intelligence to improve their research regarding new drugs. The goal is to exploit modern computational biology and machine learning systems to predict the molecular behaviour and the likelihood of getting a useful drug, thus saving time and money on unnecessary tests. Clinical studies, electronic medical records, high-resolution medical images, and genomic profiles can be used as resources to aid drug development. Pharmaceutical and medical researchers have extensive data sets that can be analyzed by strong AI systems. This review focused on how computational biology and artificial intelligence technologies can be implemented by integrating the knowledge of cancer drugs, drug resistance, next-generation sequencing, genetic variants, and structural biology in the cancer precision drug discovery.


2020 ◽  
Vol 10 (10) ◽  
pp. 3532
Author(s):  
Jesús Jaime Moreno Escobar ◽  
Oswaldo Morales Matamoros ◽  
Ricardo Tejeida Padilla ◽  
Ixchel Lina Reyes ◽  
Liliana Chanona Hernández ◽  
...  

This work presents the HSS-Cognitive project, which is a Healthcare Smart System that can be applied in measuring the efficiency of any therapy where neuronal interaction gives a trace whether the therapy is efficient or not, using mathematical tools. The artificial intelligence of the project underlies in the understanding of brain signals or Electroencephalogram (EEG) by means of the determination of the Power Spectral Density (PSD) over all the EEG bands in order to estimate how efficient was a therapy. Our project HSS-Cognitive was applied, recording the EEG signals from two patients treated for 8 min in a dolphin tank, measuring their activity in five experiments and for 6 min measuring their activity in a pool without dolphin in four experiments. After applying our TEA (Therapeutic Efficiency Assessment) metric for patient 1, we found that this patient had gone from having relaxation states regardless of the dolphin to attention states when the dolphin was presented. For patient 2, we found that he had maintained attention states regardless of the dolphin, that is, the DAT (Dolphin Assisted Therapy) did not have a significant effect in this patient, perhaps because he had a surgery last year in order to remove a tumor, having impact on the DAT effectiveness. However, patient 2 presented the best efficiency when doing physical therapy led by a therapist in a pool without dolphins around him. According to our findings, we concluded that our Brain-Inspired Healthcare Smart System can be considered a reliable tool for measuring the efficiency of a dolphin-assisted therapy and not only for therapist or medical doctors but also for researchers in neurosciences.


2019 ◽  
Vol 24 ◽  
pp. 03002
Author(s):  
Alexandra Khalyasmaa ◽  
Elena Zinovieva ◽  
Stanislav Eroshenko ◽  
Daria Shatunova

This paper is devoted to the problems and features of database creation in intelligent systems for assessing the efficiency of scientific and technical solutions. The system data model developed by the authors and the principles of its operation are described. This paper also considers the process of training sampling and the analysis of various teaching methods for solving the presented problem. The implementation of the developed model is made using mathematical modeling. The initial data was the data of applications for grants in the field of technical sciences related to the fuel and energy complex.


2019 ◽  
Vol 7 (9) ◽  
pp. 382-385
Author(s):  
Pramod Kumar

Big data in the life sciences and healthcare sectors is an increasing trend. It is the processing and displaying of huge volumes and varieties of data at a rapid speed. There is a vast amount of data in the healthcare and Pharmaceutical industries, including lab data, insurance data, patient records, research data, and even social media data (1, 2). Pharmaceutical companies have vast amounts of compounds that could be the perfect solution to combat specific diseases, but they have no way to identify them as such. The development and production of drugs can cost pharmaceutical companies up to $2.6 billion (£1.8bn) and take 12 to 14 years to complete (1). Artificial Intelligence (AI) plays a crucial role in enabling the industry to achieve these objectives, be it analytics in personalized medicine, cloud computing in collaboration, or wearable devices in remote and self-health monitoring. Thus, the main short/medium-term implication AI has for the pharmaceutical industry is the reduced time it takes to develop drugs and thus the associated costs, enhancing return on investment and could even mean a reduction in cost for end users. As the pharmaceutical industry becomes increasingly more connected, information and communication technologies will fundamentally reshape both the consumption and delivery of medications (1, 2,3).


Author(s):  
Sankha Bhattacharya

: Artificial intelligence and robotics are two of the hottest and most recent technologies to emerge from the world of science. There is tremendous potential for these technologies to solve a wide range of pharmaceutical problems, including the reduction of the enormous amounts of money and time invested in the drug discovery and development process, technical solutions related to the quality of drug products, and an increase in the demand for pharmaceuticals. Nanorobotics is a new subfield that has emerged from the field of robotics itself. This technique makes use of robots that are as small as nano- or micron-sized to diagnose diseases and deliver drugs to the targeted organ, tissue, or cell. These techniques, as well as their various applications in the pharmacy sector, are extensively discussed throughout this article. Internationally renowned pharmaceutical companies are collaborating with Artificial Intelligence behemoths in order to revolutionise the discovery and development process of potential drug molecules and to ensure the highest possible quality in their products.


Author(s):  
Adarsh Sahu ◽  
Jyotika Mishra ◽  
Namrata Kushwaha

: The advancement of computing and technology has invaded all the dimensions of science. Artificial intelligence (AI) is one core branch of Computer Science, which has percolated to all the arenas of science and technology, from core engineering to medicines. Thus, AI has found its way for application in the field of medicinal chemistry and heath care. The conventional methods of drug design have been replaced by computer-aided designs of drugs in recent times. AI is being used extensively to improve the design techniques and required time of the drugs. Additionally, the target proteins can be conveniently identified using AI, which enhances the success rate of the designed drug. The AI technology is used in each step of the drug designing procedure, which decreases the health hazards related to preclinical trials and also reduces the cost substantially. The AI is an effective tool for data mining based on the huge pharmacological data and machine learning process. Hence, AI has been used in de novo drug design, activity scoring, virtual screening and in silico evaluation in the properties (absorption, distribution, metabolism, excretion and toxicity) of a drug molecule. Various pharmaceutical companies have teamed up with AI companies for faster progress in the field of drug development, along with the healthcare system. The review covers various aspects of AI (Machine learning, Deep learning, Artificial neural networks) in drug design. It also provides a brief overview of the recent progress by the pharmaceutical companies in drug discovery by associating with different AI companies.


Author(s):  
Saranjit Singh ◽  
Geeta Rajput ◽  
R. K. Narang ◽  
Balak Das Kurmi

: Artificial intelligence and robotics are both trendy and new science word technologies. These advances can address many pharmaceutical problems, including reducing the vast amount of money and time spent on drug development and manufacturing, technical solutions related to the protection of medicinal products, and the medication demand. The new subfield of nanorobotics comes from robotics itself. In the diagnosis and supply of drugs to the target organ, tissue, and cell, robots' nano or micron-scale is used. All these strategies are extensively discussed in this review for each of their pharmacy applications. Renowned pharmaceutical companies are working together with giant Artificial Intelligence to revolutionize potential drug molecules' discovery, production, and efficiency.


Author(s):  
Ashraf Mina

AbstractBackgroundThis article is focused on the understanding of the key points and their importance and impact on the future of early disease predictive models, accurate and fast diagnosis, patient management, optimise treatment, precision medicine, and allocation of resources through the applications of Big Data (BD) and Artificial Intelligence (AI) in healthcare.ContentBD and AI processes include learning which is the acquisition of information and rules for using the information, reasoning which is using rules to reach approximate or definite conclusions and self-correction. This can help improve the detection of diseases, rare diseases, toxicity, identifying health system barriers causing under-diagnosis. BD combined with AI, Machine Learning (ML), computing and predictive-modelling, and combinatorics are used to interrogate structured and unstructured data computationally to reveal patterns, trends, potential correlations and relationships between disparate data sources and associations.SummaryDiagnosis-assisted systems and wearable devices will be part and parcel not only of patient management but also in the prevention and early detection of diseases. Also, Big Data will have an impact on payers, devise makers and pharmaceutical companies. BD and AI, which is the simulation of human intelligence processes, are more diverse and their application in monitoring and diagnosis will only grow bigger, wider and smarter.OutlookBD connectivity and AI of diagnosis-assisted systems, wearable devices and smartphones are poised to transform patient and to change the traditional methods for patient management, especially in an era where is an explosion in medical data.


Sign in / Sign up

Export Citation Format

Share Document